0.78
-0.023(-2.86%)
Currency In USD
| Previous Close | 0.8 |
| Open | 0.81 |
| Day High | 0.81 |
| Day Low | 0.78 |
| 52-Week High | 1.24 |
| 52-Week Low | 0.54 |
| Volume | 43,299 |
| Average Volume | 239,745 |
| Market Cap | 9.09M |
| PE | -0.52 |
| EPS | -1.5 |
| Moving Average 50 Days | 0.83 |
| Moving Average 200 Days | 0.84 |
| Change | -0.02 |
If you invested $1000 in Biofrontera Inc. (BFRI) since IPO date, it would be worth $8.84 as of January 14, 2026 at a share price of $0.78. Whereas If you bought $1000 worth of Biofrontera Inc. (BFRI) shares 3 years ago, it would be worth $39 as of January 14, 2026 at a share price of $0.78.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth
GlobeNewswire Inc.
Yesterday at 1:30 PM GMT
Fourth quarter results represent highest quarterly revenue in Company’s historyQ4 year-over-year growth of 35% to 39% driven by sales execution of Ameluz®Full year 2025 revenues also expected to show double-digit growth of 11% to 13% WOBURN, Mass., J
Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones
GlobeNewswire Inc.
Jan 08, 2026 1:45 PM GMT
Database locks for studies on actinic keratosis (AK) and acne vulgaris achieved on January 5, 2026Data generated will support key regulatory milestones for Ameluz PDT in both indicationsAK and acne are the two most commonly diagnosed skin disorders i
Biofrontera Inc. Completes Transfer of Ameluz® and RhodoLED® FDA approval and Associated Intellectual Property Portfolio
GlobeNewswire Inc.
Dec 18, 2025 1:45 PM GMT
• Ameluz® and RhodoLED® New Drug Application (NDA) and Investigational New Drug Application (IND) have successfully been transferred to Biofrontera Inc.• Assignment to Biofrontera Inc. of 11 granted US patents, 10 pending US patent applications and v